Long-term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease.
OBJECTIVE
The aim of the present study was to evaluate the effects of HRT on symptoms of angina pectoris, quality of life and factors of importance for compliance in women with ischemic heart disease.


METHODS
Sixty postmenopausal women with coronary artery disease were randomized into three groups: one group received transdermal 17 beta-estradiol at a dose of 50 micrograms per 24 h alone for 18 days followed by 10 days of combined treatment with medroxyprogesterone acetate (MPA) 5 mg orally; the second group received placebo and the third group received conjugated estrogens orally for 18 days followed by a combined treatment with MPA for 10 days. Clinical evaluations were performed at baseline, after 3, 6 and 12 months. The investigations included gynecological history. occurrence of climacteric symptoms, quality of life evaluation, cardiac history and symptoms of angina pectoris.


RESULTS
Forty-six women (77%) completed the study during 1 year. The following cardiac events occurred in the women who completed the study: one patient was hospitalized because of congestive heart failure (patch), two patients because of angina pectoris, one patient because of coronary bypass operation (CEE) and three patients underwent balloon dilatation (placebo), all three on CEE. Among the 14 women who discontinued, two patients had TIA (patch), one experienced palpitations (CEE) and one woman died from myocardial infarction (placebo). Overall improvement in mood and cognitive functions were reported in all three treatment groups.


CONCLUSIONS
HRT does not seem to have negative effects on symptoms of angina pectoris and seems to increase quality of life in older women with coronary heart disease. It also seems safe from the cardiovascular point of view.
Hall
G
G
Department of Woman and Child Health, Karolinska Hospital/Institute, Stockholm, Sweden.
Pripp
U
U
Schenck-Gustafsson
K
K
Landgren
B M
BM
D000368:Aged; D000787:Angina Pectoris / Q000097:blood / Q000378:metabolism / Q000503:physiopathology*; D015331:Cohort Studies; D003327:Coronary Disease / Q000150:complications*; D004958:Estradiol / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy / Q000009:adverse effects* / Q000379:methods / Q000592:standards; D004966:Estrogens, Conjugated (USP) / Q000494:pharmacology / Q000627:therapeutic use; D004970:Estrone / Q000031:analogs & derivatives / Q000097:blood / Q000378:metabolism; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood / Q000378:metabolism; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000494:pharmacology / Q000627:therapeutic use; D008875:Middle Aged; D010349:Patient Compliance; D017698:Postmenopause / Q000097:blood / Q000187:drug effects* / Q000523:psychology; D045167:Progesterone Congeners / Q000494:pharmacology / Q000627:therapeutic use; D011788:Quality of Life; D012449:Safety; D013997:Time Factors
D004966:Estrogens, Conjugated (USP); D045167:Progesterone Congeners; D004970:Estrone; D004958:Estradiol; D005640:Follicle Stimulating Hormone; D017258:Medroxyprogesterone Acetate; C017296:estrone sulfate